The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage- and disease-dependent epigenetic remodeling.
A549 Cells
Binding Sites
/ genetics
Cell Line
Chromatin
/ genetics
Enhancer Elements, Genetic
Epigenesis, Genetic
Gain of Function Mutation
Gene Expression Regulation
Genetic Predisposition to Disease
Humans
Idiopathic Pulmonary Fibrosis
/ genetics
Lung
/ metabolism
Models, Genetic
Mucin-5B
/ genetics
Polymorphism, Single Nucleotide
Proto-Oncogene Proteins c-ets
/ metabolism
RNA Polymerase II
/ metabolism
STAT3 Transcription Factor
/ metabolism
Fibrosis
Genetic variation
Pulmonology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
25 01 2021
25 01 2021
Historique:
received:
17
09
2020
accepted:
09
12
2020
pubmed:
16
12
2020
medline:
5
6
2021
entrez:
15
12
2020
Statut:
epublish
Résumé
The G/T transversion rs35705950, located approximately 3 kb upstream of the MUC5B start site, is the cardinal risk factor for idiopathic pulmonary fibrosis (IPF). Here, we investigate the function and chromatin structure of this -3 kb region and provide evidence that it functions as a classically defined enhancer subject to epigenetic programming. We use nascent transcript analysis to show that RNA polymerase II loads within 10 bp of the G/T transversion site, definitively establishing enhancer function for the region. By integrating Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analysis of fresh and cultured human airway epithelial cells with nuclease sensitivity data, we demonstrate that this region is in accessible chromatin that affects the expression of MUC5B. Through applying paired single-nucleus RNA- and ATAC-seq to frozen tissue from IPF lungs, we extend these findings directly to disease, with results indicating that epigenetic programming of the -3 kb enhancer in IPF occurs in both MUC5B-expressing and nonexpressing lineages. In aggregate, our results indicate that the MUC5B-associated variant rs35705950 resides within an enhancer that is subject to epigenetic remodeling and contributes to pathologic misexpression in IPF.
Identifiants
pubmed: 33320836
pii: 144294
doi: 10.1172/jci.insight.144294
pmc: PMC7934873
doi:
pii:
Substances chimiques
Chromatin
0
MUC5B protein, human
0
Mucin-5B
0
Proto-Oncogene Proteins c-ets
0
SPDEF protein, human
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
RNA Polymerase II
EC 2.7.7.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : S10 OD012300
Pays : United States
Organisme : NHLBI NIH HHS
ID : UH3 HL151865
Pays : United States
Organisme : BLRD VA
ID : I01 BX005295
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007085
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM125871
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL149836
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141264
Pays : United States
Organisme : NHLBI NIH HHS
ID : UH3 HL123442
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3 HL151865
Pays : United States
Références
Nat Commun. 2018 Dec 18;9(1):5363
pubmed: 30560893
Elife. 2020 Nov 09;9:
pubmed: 33164753
Sci Adv. 2020 Jul 08;6(28):eaba1972
pubmed: 32832598
Exp Lung Res. 2002 Jun;28(4):315-32
pubmed: 12042033
Am J Respir Cell Mol Biol. 2011 Aug;45(2):246-52
pubmed: 20935193
Genome Res. 2017 Nov;27(11):1816-1829
pubmed: 29025894
Semin Cancer Biol. 2018 Oct;52(Pt 1):74-84
pubmed: 28855104
Nat Protoc. 2016 Aug;11(8):1455-76
pubmed: 27442863
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
Clin Epigenetics. 2019 Dec 2;11(1):174
pubmed: 31791394
Molecules. 2018 May 10;23(5):
pubmed: 29748466
Nat Rev Genet. 2016 Apr;17(4):207-23
pubmed: 26948815
PLoS One. 2018 Nov 27;13(11):e0207915
pubmed: 30481203
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18602-7
pubmed: 24173036
Allergy. 2017 Jul;72(7):1043-1053
pubmed: 27878831
Methods Mol Biol. 2012;833:63-87
pubmed: 22183588
J Clin Med. 2018 Aug 06;7(8):
pubmed: 30082599
Nucleic Acids Res. 2015 Aug 18;43(14):6959-68
pubmed: 26117547
J Clin Invest. 2009 Oct;119(10):2914-24
pubmed: 19759516
Nat Genet. 2013 Jun;45(6):613-20
pubmed: 23583980
Am J Respir Cell Mol Biol. 2018 Sep;59(3):383-396
pubmed: 29579396
Nat Commun. 2019 May 20;10(1):2229
pubmed: 31110176
Methods Mol Biol. 2018;1809:91-109
pubmed: 29987785
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Genes Dev. 1997 Feb 15;11(4):436-50
pubmed: 9042858
Curr Opin Genet Dev. 2010 Oct;20(5):527-32
pubmed: 20591647
Mol Cell. 2018 Aug 2;71(3):375-388
pubmed: 29887393
Oncotarget. 2017 Jul 25;8(30):48737-48754
pubmed: 28467787
Am J Respir Cell Mol Biol. 2007 Nov;37(5):589-97
pubmed: 17600309
Cancers (Basel). 2019 Nov 28;11(12):
pubmed: 31795213
Int J Biochem Cell Biol. 2017 Jul;88:124-132
pubmed: 28478266
N Engl J Med. 2013 Jun 6;368(23):2192-200
pubmed: 23692170
Am J Respir Crit Care Med. 2018 Sep 1;198(5):599-609
pubmed: 29924937
Curr Opin Pulm Med. 2015 Sep;21(5):454-62
pubmed: 26176965
Oncogene. 2007 Oct 4;26(45):6566-76
pubmed: 17471237
Am J Respir Crit Care Med. 2019 Jul 15;200(2):220-234
pubmed: 30973754
Science. 2015 May 22;348(6237):910-4
pubmed: 25953818
Cell. 2013 Apr 11;153(2):307-19
pubmed: 23582322
Nucleic Acids Res. 2018 Jan 4;46(D1):D252-D259
pubmed: 29140464
J Biol Chem. 2019 Dec 6;294(49):18726-18741
pubmed: 31666338
Elife. 2014 May 27;3:e02200
pubmed: 24867637
EMBO Mol Med. 2017 Apr;9(4):462-481
pubmed: 28255028
Biochim Biophys Acta. 2012 Jan;1821(1):57-69
pubmed: 21515403
Curr Top Med Chem. 2017;17(6):631-662
pubmed: 27320335
Toxicology. 2001 Mar 7;160(1-3):35-46
pubmed: 11246122
Pharmacol Ther. 2019 Dec;204:107406
pubmed: 31521697
Genome Res. 2019 Nov;29(11):1753-1765
pubmed: 31519741
Nat Rev Drug Discov. 2017 Nov;16(11):755-772
pubmed: 28983101
Mol Cell Endocrinol. 2006 Mar 27;248(1-2):149-59
pubmed: 16406653
Am J Respir Cell Mol Biol. 2017 Jul;57(1):91-99
pubmed: 28272906
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Transl Res. 2015 Jan;165(1):48-60
pubmed: 24746870
Nucleic Acids Res. 2016 Jan 4;44(D1):D717-25
pubmed: 26590259
PLoS One. 2013;8(3):e58658
pubmed: 23527003
Am J Respir Crit Care Med. 2016 Feb 15;193(4):464-6
pubmed: 26871673
Cell. 2018 Oct 4;175(2):598-599
pubmed: 30290144
J Math Biol. 2017 Jan;74(1-2):77-97
pubmed: 27142882
Nat Methods. 2017 Oct;14(10):959-962
pubmed: 28846090
Nat Struct Mol Biol. 2019 Oct;26(10):841
pubmed: 31582845
Nature. 2014 Jan 16;505(7483):412-6
pubmed: 24317696
Lancet Respir Med. 2013 Jun;1(4):309-317
pubmed: 24429156
N Engl J Med. 2011 Apr 21;364(16):1503-12
pubmed: 21506741
Am J Respir Crit Care Med. 2016 Feb 15;193(4):462-4
pubmed: 26871672
Genome Res. 2018 Feb 15;:
pubmed: 29449408
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell Signal. 2020 Feb;66:109482
pubmed: 31760172
Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208
pubmed: 31034279
Biochim Biophys Acta. 2011 Aug;1812(8):956-63
pubmed: 21295138
Am J Respir Crit Care Med. 2019 Mar 15;199(6):715-727
pubmed: 30352166
Novartis Found Symp. 2006;279:155-66; discussion 167-9, 216-9
pubmed: 17278393
Mol Cell Biol. 2013 Jun;33(11):2104-15
pubmed: 23508109
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536
pubmed: 30554520
Biochem Cell Biol. 2015 Apr;93(2):159-70
pubmed: 25659821
JCI Insight. 2016 Dec 8;1(20):e90558
pubmed: 27942595